Newland Pharmaceutical (301277.SZ): Marketing application for Fondaparinux Sodium API approved
Newland Pharmaceutical (301277.SZ) announced that the company recently received the "Chemical API Marketing Application Approval Notification" issued by the National Medical Products Administration for Fondaparinux Sodium API. Fondaparinux Sodium is a synthetic selective factor Xa inhibitor with a uniform composition and contains no animal-derived components. Its indications include the prevention of venous thromboembolism after major orthopedic surgeries such as hip fracture and hip/knee replacement, and it can also be used for anticoagulant therapy in deep vein thrombosis, pulmonary embolism, and acute coronary syndrome.
Newland Pharmaceutical (301277.SZ) announced that the company recently received the "Chemical API Marketing Application Approval Notice" for Fondaparinux Sodium API issued by the National Medical Products Administration. Fondaparinux Sodium is a synthetic selective coagulation factor Xa inhibitor with a uniform composition and contains no animal-derived components. Its indications include the prevention of venous thromboembolism after major orthopedic surgeries such as hip fracture and hip or knee replacement, and it can also be used for anticoagulant therapy in deep vein thrombosis, pulmonary embolism, and acute coronary syndrome.
Related Articles
SCHOLAR EDU (01769): Trustee purchases 252,000 shares under the share award scheme
HASHKEY HLDGS (03887) repurchased 420,000 shares for HK$966,500 on October 7.
KINDSTAR GLOBAL (09960) repurchased 2,000 shares for HKD 1,870 on October 7.
SCHOLAR EDU (01769): Trustee purchases 252,000 shares under the share award scheme
HASHKEY HLDGS (03887) repurchased 420,000 shares for HK$966,500 on October 7.
KINDSTAR GLOBAL (09960) repurchased 2,000 shares for HKD 1,870 on October 7.
